Prediction of response to infliximab in Crohn's disease

被引：7

作者：

Chaudhary, R ^{[1
]}

Ghosh, S ^{[1
]}

机构：

[1] Hammersmith Hosp, Imperial Coll London, Gastrointestinal Sect, London W12 0NN, England

来源：

DIGESTIVE AND LIVER DISEASE | 2005年 / 37卷 / 08期

关键词：

D O I：

10.1016/j.dld.2005.04.002

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：559 / 563

页数：5

共 22 条

[1] An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease [J].

Arnott, IDR ;

McNeill, G ;

Satsangi, J .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 17 (12) :1451-1457

[2] C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis - Defining subtypes of nonresponse and subsequent response to etanercept [J].

Buch, MH ;

Seto, Y ;

Bingham, SJ ;

Bejarano, V ;

Bryer, D ;

White, J ;

Emery, P .

ARTHRITIS AND RHEUMATISM, 2005, 52 (01) :42-48

[3] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[4]

Esters N, 2002, AM J GASTROENTEROL, V97, P1458

[5] Maintenance therapy versus episodic therapy with infliximab for Crohn's disease [J].

Ghosh, Subrata .

NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2004, 1 (02) :80-81

[6] Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial [J].

Hanauer, SB ;

Feagan, BG ;

Lichtenstein, GR ;

Mayer, LF ;

Schreiber, S ;

Colombel, JF ;

Rachmilewitz, D ;

Wolf, DC ;

Olson, A ;

Bao, WH ;

Rutgeerts, P .

LANCET, 2002, 359 (9317) :1541-1549

[7] Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: Clinical experience with 400 infusions [J].

Kinney, T ;

Rawlins, M ;

Kozarek, R ;

France, R ;

Patterson, D .

AMERICAN JOURNAL OF GASTROENTEROLOGY, 2003, 98 (03) :608-612

[8] Response to infliximab is related to disease duration in paediatric Crohn's disease [J].

Lionetti, P ;

Bronzini, F ;

Salvestrini, C ;

Bascietto, C ;

Canani, RB ;

Dé Angelis, GL ;

Guariso, G ;

Martelossi, S ;

Papadatou, B ;

Barabino, A .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2003, 18 (04) :425-431

[9] Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease [J].

Louis, E ;

El Ghoul, Z ;

Vermeire, S ;

Dall'Ozzo, S ;

Rutgeerts, P ;

Paintaud, G ;

Belaiche, J ;

De Vos, M ;

Van Gossum, A ;

Colombel, JF ;

Watier, H .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2004, 19 (05) :511-519

[10] A positive response to infliximab in Crohn disease: Association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism [J].

Louis, E ;

Vermeire, S ;

Rutgeerts, P ;

De Vos, M ;

Van Gossum, A ;

Pescatore, P ;

Fiasse, R ;

Pelckmans, P ;

Reynaert, H ;

D'Haens, G ;

Malaise, M ;

Belaiche, J .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2002, 37 (07) :818-824

← 1 2 3 →